2018-06-19 16:02:51 | Bristol-Myers treatment of gastric cancer granted FDA orphan designationBristol-Myers Squibb's fixed dose combination of relatlimab and nivolumab was granted FDA orphan designation as a treatment of gastric cancer and gastro-esophageal junction cancer, according to a post to the agency's website. Reference Link | |
---|---|---|
![]() ![]()
|
| | |
| ||
| ||
| | |
|
| ||
| ||
| ||
| | |
|
| ||
| ||
| ||
| | |
| |
| ||
| | |
| | |
| | |
|
| ||
| | |
, |
| |
| ||
| |